SCHEMBL29480650

SCHEMBL29480650

CC(=O)N1CCC(C(O)(c2ccc(-n3cc(-c4ccnc5[nH]cnc45)cn3)nc2)C(F)(F)F)CC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP3K12 Q12852 1/20 0.34
▸ CDK9 P50750 4/20 0.34
▸ CASP3 P42574 2/20 0.34
▸ CASP7 P55210 2/20 0.34
▸ CCNT1 O60563 2/20 0.34
▸ HDAC4 P56524 1/20 0.33
▸ JAK1 P23458 5/20 0.32
▸ GRM4 Q14833 1/20 0.32
▸ MAP3K7 O43318 1/20 0.31
▸ TAB1 Q15750 1/20 0.31
▸ RIPK2 O43353 2/20 0.31
▸ JAK2 O60674 1/20 0.31
▸ SYK P43405 1/20 0.31
▸ IRAK1 P51617 1/20 0.31
▸ IRAK4 Q9NWZ3 1/20 0.31
▸ KDM4A O75164 1/20 0.31
▸ KDM4B O94953 1/20 0.31
▸ KDM5C P41229 1/20 0.31
▸ KDM5B Q9UGL1 1/20 0.31
▸ RORC P51449 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22735730 1.00 MAP3K12 (0.34) MAP3K12CDK9CASP3CASP7CCNT1
SCHEMBL22716889 0.92 JAK1 (0.35) HDAC4JAK1JAK2SYKALDH1A1
SCHEMBL29567498 0.92 JAK1 (0.35) HDAC4JAK1JAK2SYKALDH1A1
SCHEMBL22735711 0.92 HDAC4 (0.34) CDK9CCNT1HDAC4JAK1JAK2
SCHEMBL29480666 0.92 HDAC4 (0.34) CDK9CCNT1HDAC4JAK1JAK2
SCHEMBL22735904 0.91 KDM4A (0.36) HDAC4GRM4KDM4AKDM4BKDM5C
SCHEMBL29480485 0.91 KDM4A (0.36) HDAC4GRM4KDM4AKDM4BKDM5C
SCHEMBL22736027 0.90 HDAC4 (0.34) HDAC4JAK1GRM4JAK2
SCHEMBL29480597 0.90 HDAC4 (0.34) HDAC4JAK1GRM4JAK2
SCHEMBL22735900 0.89 HDAC4 (0.33) HDAC4JAK1GRM4KDM4AKDM4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12516056-B2 Compounds for inhibition of janus kinase 1 MANKIND PHARMA LTD. (IN) 2026-01-06 — — US disclosed
US-20220235046-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD. (IN) 2022-07-28 — — US disclosed
EP-3976612-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD (IN) 2022-04-06 — — EP disclosed
CN-114174294-A Novel compounds for inhibiting JANUS kinase 1 人类制药有限公司 2022-03-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235046-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 JAK1, JAK2, JAK3 MAP3K12 31/4885CDK9 80/4885CASP3 2775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback